Tag: LAA closure
Append Medical raises US$4.35 million in initial closing of extended series...
Append Medical has raised US$4.35 million as part of an extended series A round, which will be used to support the company's first-in-human trials of Appligator.
Investors include...
Preclinical study outlines key features of foam-based LAA closure device
A preclinical study demonstrating key features of the foam-based left atrial appendage closure device (CLAAS, Conformal Medical) has been published in the Journal of...
Novel device “safely obliterates” left atrial appendage with minimal amount left...
The novel left atrial appendage (LAA) closure device Appligator (Append Medical) was a finalist in the 2019 ICI Innovation Award Competition (Innovation in Cardiovascular...
Pooled analysis shows LAAC is cheaper than drug therapy for AF
A pooled analysis of five-year data from the PROTECT AF and PREVAIL trials has shown left atrial appendage closure (LAAC) to be cost‐effective, and...
White paper from Heart Rhythm Society suggests Afib treatment has reached...
The Heart Rhythm Society has published a white paper looking at the consequences of oral anticoagulants for managing stroke risk in atrial fibrillation which...
Vivek Reddy on the final outcomes of PREVAIL and PROTECT-AF
Boston Scientific has announced the final five-year outcomes data from the PREVAIL study during a late-breaking clinical trial session at this year’s Transcatheter Cardiovascular...
Analysis of LAA closure devices reveals post-approval spike in safety events
A retrospective study conducting a safety assessment and comparison between two percutaneous devices commonly used for left atrial appendage (LAA) closure in the US...
Left atrial appendage closure during heart surgery protects the brain from...
Closure of the left atrial appendage during open heart surgery protects the brain from infarctions and stroke, and could be routinely performed in the future,...
CSI 2017: Global postmarket surveillance study to explore use of LAmbre...
LifeTech, at the 2017 Congenital and Structural Intervention Congress (CSI; 28 June—1 July, Frankfurt, Germany), announced the launch of a three-year global postmarket surveillance...